SEC Form 4 · accession 0000950138-18-000427
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Trudeau
Officer — President and CEO · Director
Period of report
May 16, 2018
Accepted (ET)
May 18, 2018 · 4:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | May 16, 2018 | P | 3,000 | $15.5382 | A | 269,961 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $15.525 to $15.55, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range.
- F2Includes 1,062 shares acquired on March 31, 2018 under the Mallinckrodt employee stock purchase plan.
Remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.